Tony Chuong, MD
Internal Medicine · Arlington, TXNPI 1922056803
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 451 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,561 and has fallen 51.3% since, to $760 in 2025. Among internal medicine clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 451 payments — averaging $16.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Gilead$877
- Lilly USA, LLC$500
- AbbVie$435
- AstraZeneca$396
- Merck$386
- plus $3K from 31 others
What the payments were for
- Food & beverage$7,21699%
- Education$951%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 84 | $1,272 |
| Gilead | 44 | $877 |
| Lilly USA, LLC | 29 | $500 |
| AbbVie(2 entities) | 29 | $435 |
| AstraZeneca | 26 | $396 |
| Merck | 26 | $386 |
| Amgen(2 entities) | 24 | $382 |
| GSK | 25 | $368 |
| Bayer | 21 | $352 |
| Amarin Pharma, Inc. | 20 | $289 |
| Pfizer | 15 | $256 |
| Boehringer Ingelheim | 15 | $235 |
| Astellas Pharma US Inc | 9 | $199 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $171 |
| Exact Sciences | 11 | $171 |
| Abbott | 6 | $142 |
| Genentech USA, Inc. | 7 | $106 |
| Johnson & Johnson(2 entities) | 8 | $102 |
| Novartis | 6 | $98 |
| Kowa Pharmaceuticals America, Inc. | 7 | $93 |
| Eisai Inc. | 3 | $56 |
| Althera Pharmaceuticals LLC | 4 | $50 |
| Dexcom, Inc. | 2 | $45 |
| Scilex Pharmaceuticals Inc. | 2 | $43 |
| Nestle Healthcare Nutrition Inc. | 3 | $40 |
| Sanofi Pasteur Inc. | 2 | $34 |
| Idorsia Pharmaceuticals US Inc | 2 | $28 |
| Corcept Therapeutics | 1 | $25 |
| Biohaven Pharmaceuticals, Inc. | 1 | $25 |
| Optinose US, Inc. | 1 | $25 |
| Boston Scientific | 1 | $22 |
| Verona Pharma, Inc. | 1 | $20 |
| Redhill Biopharma Inc. | 1 | $14 |
| Lifescan, Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Paratek Pharmaceuticals, Inc. | 1 | $13 |
| Hologic Sales And Service, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$109
How this compares
$7,311 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 250 | $325,810 |
| JardianceEmpagliflozin | 209 | $273,852 |
| RybelsusSemaglutide | 114 | $184,118 |
| OzempicSemaglutide | 86 | $124,058 |
| TrulicityDulaglutide | 50 | $102,593 |
| JanuviaSitagliptin Phosphate | 77 | $90,541 |
| ProliaDenosumab | 41 | $71,779 |
| EliquisApixaban | 46 | $66,868 |
| Omega-3 Acid Ethyl Esters | 246 | $52,721 |
| JanumetSitagliptin Phos/Metformin Hcl | 38 | $51,519 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 62 | $48,497 |
| TradjentaLinagliptin | 26 | $40,409 |
| LinzessLinaclotide | 29 | $37,160 |
| KerendiaFinerenone | 31 | $33,417 |
| MounjaroTirzepatide | 18 | $31,104 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $396 | $344,411275 claims |
| Boehringer IngelheimJardiance, Tradjenta | $235 | $314,261235 claims |
| Novo NordiskRybelsus, Ozempic | $1,272 | $308,176200 claims |
| MerckJanuvia, Janumet | $386 | $142,060115 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $500 | $133,69768 claims |
| AmgenProlia | $382 | $71,77941 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix | $368 | $71,416125 claims |
| PfizerEliquis | $256 | $66,86846 claims |
| AbbVieLinzess, Restasis | $435 | $66,02666 claims |
| BayerKerendia | $352 | $33,41731 claims |
| Johnson & JohnsonXarelto | $102 | $11,92315 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $93 | $11,17816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Arlington
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Mohammed Al-NajjarEl Paso$586K
- Han SchmidlyDallas$465K
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
- Nitin JainHouston$281K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.